Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 19/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5155290 | 0.79 | GCK (0.37) | CA2CA1CA4CA7 | |
| SCHEMBL8122844 | 0.79 | ALDH1A1 (0.38) | CA2 | |
| SCHEMBL2008068 | 0.76 | CA2 (0.52) | CA2CA1CA4CA7CA12 | |
| SCHEMBL28047295 | 0.76 | CA2 (0.59) | CA2 | |
| SCHEMBL23531742 | 0.74 | CA2 (0.50) | CA2CA1CA4CA7CA12 | |
| SCHEMBL28189287 | 0.74 | CA2 (0.50) | CA2CA1CA4CA7CA12 | |
| SCHEMBL2009694 | 0.74 | CA2 (0.58) | CA2CA1CA12CA9CCNE1 | |
| SCHEMBL4645608 | 0.74 | CA2 (0.50) | CA2CA1CA4CA7CA12 | |
| SCHEMBL14336418 | 0.74 | CA2 (0.34) | CA2CA1CA4CA7CA12 | |
| SCHEMBL27452903 | 0.71 | CA2 (0.53) | CA2CA1CA4CA7CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105237523-B | Pyrimidine derivatives and preparation method thereof, purposes | 深圳市博圣康生物科技有限公司 | 2018-06-01 | — | — | CN | claimed |
| CN-105237523-A | Pyrimidine derivatives, and preparation method and use thereof | SHENZHEN BIOSCIEN PHARMACEUTICALS CO LTD | 2016-01-13 | — | — | CN | claimed |
| CN-119585247-A | Bicyclic heterocyclic amide inhibitors of nav1.8 for the treatment of pain | 赛特温治疗公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4514789-A1 | <SUP2/>? <SUB2/>?V?BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA1.8 FOR THE TREATMENT OF PAIN | SiteOne Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| CN-105237523-B | Pyrimidine derivatives and preparation method thereof, purposes | 深圳市博圣康生物科技有限公司 | 2018-06-01 | — | — | CN | disclosed |
| CN-105237523-A | Pyrimidine derivatives, and preparation method and use thereof | SHENZHEN BIOSCIEN PHARMACEUTICALS CO LTD | 2016-01-13 | — | — | CN | disclosed |
| US-7288547-B2 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2007-10-30 | — | — | US | disclosed |
| US-7288547-B2 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2007-10-30 | — | — | US | disclosed |
| US-7288547-B2 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2007-10-30 | — | — | US | disclosed |
| EP-1483260-A1 | CDK INHIBITING 2-HETEROARYL PYRIMIDINE, THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Schering Aktiengesellschaft (DE) | 2004-12-08 | — | — | EP | disclosed |
| US-20040063737-A1 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2004-04-01 | — | — | US | disclosed |
| WO-2003076437-A1 | CDK INHIBITING 2-HETEROARYL PYRIMIDINE, THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063737-A1 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK6, CDKL2 | CA2 3633/4885CA1 4738/4885CA4 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.